{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
osimertinib
to a specific field?
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
AZ5104 is a demethylated metabolite of Osimertinib. AZ5104 potently and irreversibly inhibits both wild-type and mutant (exon 19 and L858R) EGFR and demonstrates good anti-cancer effect in both cell-based and in vivo experiments. Although AZ5104 was tested on preclinical models of lung cancer, it is used only in the prodrug form.
Status:
Other
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Investigational
Source:
NCT03428022: Phase 3 Interventional Unknown status NSCLC
(2017)
Source URL:
Class:
PROTEIN
![Structure of N-[4-[2-Amino-5-[4-[(2R)-1,4-dioxan-2-ylmethoxy]-3-methoxyphenyl]-3-pyridinyl]-3-fluorophenyl]-1?,4?-dihydro-5-methyl-4?-oxo-1?-[(tetrahydro-2H-pyran-4-yl)methyl][2,3?-bipyridine]-5?-carboxamide](/img/30c170a4-9b76-52fc-f709-62a417728d11.svg?size=200&context=rmbagftlry)
